See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. The Food and Drug Administration (FDA) on Wednesday approved Rasonque, ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

The Food and Drug Administration has approved a new pancreatic cancer drug, a pill that nearly doubled patients’ average survival times for one of the deadliest cancers when taken instead of ...

The U.S. FDA has approved Revolution Medicines’ groundbreaking pancreatic cancer drug after it was shown to double the survival rate of patients with advanced disease in a large trial, offering new ...

The Food and Drug Administration on Wednesday approved a groundbreaking new drug for advanced pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of ...

For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within ...

Companies are testing dozens of similar drugs in cancers of the pancreas, lung, colon and more. By Rebecca Robbins and Carolyn Y. Johnson The Food and Drug Administration’s approval on Wednesday of a ...

Revolution prices Rasonque at $39,800 for a 30-day supply in the US FDA reviewed drug under expedited pathway designed to cut timelines to one to two months Doctors say targeting the RAS pathway could ...

The U.S. Food and Drug Administration just approved a new breakthrough drug for pancreatic cancer that significantly extends the lives of people with the disease—considered one of the most intractable ...

FDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of cancer The US Food and Drug Administration (FDA) approved a groundbreaking new drug for the most ...

For four decades, cancer researchers fought to disable a stubborn mutation that made pancreatic cancer a death sentence—to little avail. Now, doctors have a medicine that targets the mutation. The ...

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy. By Gina Kolata Rebecca Robbins and Carolyn Y. Johnson The Food and Drug ...